Lack of predictive tools for conventional and targeted cancer therapy: barriers to biomarker development and clinical translation

Research output: Contribution to journalArticlepeer-review

26 Downloads (Pure)

Abstract

Predictive tools, utilising biomarkers, aim to objectively assess the potential response to a particular clinical intervention in order to direct treatment. Conventional cancer therapy remains poorly served by predictive biomarkers, despite being the mainstay of treatment for most patients. In contrast, targeted therapy benefits from a clearly defined protein target for potential biomarker assessment.

We discuss potential data sources of predictive biomarkers for conventional and targeted therapy, including patient clinical data and multi-omic biomarkers (genomic, transcriptomic and protein expression). Key examples, either clinically adopted or demonstrating promise for clinical translation, are highlighted. Following this, we provide an outline of potential barriers to predictive biomarker development; broadly discussing themes of approaches to translational research and study/trial design, and the impact of cellular and molecular tumor heterogeneity. Future avenues of research are also highlighted.
Original languageEnglish
Article number113854
JournalAdvanced Drug Delivery Reviews
Volume176
Early online date27 Jun 2021
DOIs
Publication statusPublished - Sep 2021

Keywords

  • Intra-tumoral heterogeneity
  • Liquid biopsy
  • Multi-omics
  • Predictive biomarker
  • Predictive signature
  • Predictive tool
  • Treatment response
  • Trial design
  • Tumor microenvironment

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Lack of predictive tools for conventional and targeted cancer therapy: barriers to biomarker development and clinical translation'. Together they form a unique fingerprint.

Cite this